福泰制药(VRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VRTX 福泰制药

休市中 10-30 16:00:00 EDT

558.88

+18.88

+3.50%

盘后554.00

-4.88-0.87%

19:59 EDT

最高563.80	最低549.89	成交量303.00万
今开550.73	昨收540.00	日振幅2.58%
总市值1,418亿	流通市值1,418亿	总股本2.54亿
成交额16.92亿	换手率1.19%	流通股本2.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VRTX","market":"US","secType":"STK","nameCN":"福泰制药","latestPrice":558.88,"timestamp":1793390400000,"preClose":540,"halted":0,"volume":3030027,"hourTrading":{"tag":"盘后","latestPrice":554,"preClose":558.88,"latestTime":"19:59 EDT","volume":219918,"amount":122902146.2647,"timestamp":1793404779529,"change":-4.88,"changeRate":-0.008732,"amplitude":0.009841},"delay":0,"changeRate":0.03496296296296295,"floatShares":253718831,"shares":253718831,"eps":17.182146,"marketStatus":"休市中","change":18.88,"latestTime":"10-30 16:00:00 EDT","open":550.73,"high":563.7995,"low":549.89,"amount":1692228265.1274002,"amplitude":0.025758,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":17.182146,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793610000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":540,"preHourTrading":{"tag":"盘前","latestPrice":550.14,"preClose":540,"latestTime":"09:29 EDT","volume":24486,"amount":13260741.0012,"timestamp":1793366999988,"change":10.14,"changeRate":0.018778,"amplitude":0.037287},"postHourTrading":{"tag":"盘后","latestPrice":554,"preClose":558.88,"latestTime":"19:59 EDT","volume":219918,"amount":122902146.2647,"timestamp":1793404779529,"change":-4.88,"changeRate":-0.008732,"amplitude":0.009841},"volumeRatio":2.5817315238517082,"impliedVol":0.5001,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/VRTX","defaultTab":"news","newsList":[{"id":"1170507140","title":"异动解读｜福泰制药盘中上涨3.89%，财报预期增长与机构看多延续提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1170507140","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170507140?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:05","pubTimestamp":1793369101,"startTime":"0","endTime":"0","summary":"10月30日，福泰制药盘中上涨3.89%，报556.4美元/股，成交额1.9亿美元。消息面上，市场对公司最新季度业绩预期偏乐观，叠加机构近期维持积极评级并上调目标价，带动股价继续走强。已披露信息显示，市场预期公司本季营收同比增长11.75%；上季度营收33.34亿美元，同比增长12.45%。公司此前还将全年营收指引上调至131亿至132亿美元；高盛将目标价微调至654美元，Leerink Partners给予跑赢大盘评级及594美元目标价。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"福泰制药盘中上涨，机构看多提振情绪","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153332542","title":"异动解读｜福泰制药盘中上涨3.16%，财报预期增长与机构看多延续提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1153332542","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153332542?lang=zh_cn&edition=full","pubTime":"2026-10-29 21:55","pubTimestamp":1793282106,"startTime":"0","endTime":"0","summary":"10月29日，福泰制药盘中上涨3.16%，报545.64美元/股，成交额8509.22万美元。消息面上，市场对公司最新季度业绩预期偏乐观，叠加多家机构近期上调目标价并维持积极评级，带动股价走强。已披露数据显示，公司上季度营收33.34亿美元，同比增长12.45%；8月公司还将全年营收指引上调至131亿至132亿美元。机构方面，高盛10月将目标价微调至654美元，Leerink Partners于9月恢复覆盖并给予跑赢大盘评级及594美元目标价。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"福泰制药盘中上涨，业绩预期与机构看多共推","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197112368","title":"异动解读｜福泰制药盘前上涨3.36%，财报前瞻与机构连续看多提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1197112368","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197112368?lang=zh_cn&edition=full","pubTime":"2026-10-29 19:26","pubTimestamp":1793273210,"startTime":"0","endTime":"0","summary":"10月29日，福泰制药盘前上涨3.36%，报545.0美元/股，成交额43.9万美元。消息面上，公司将于11月2日盘后发布最新季度财报，市场预期本季营收同比增长11.75%，主营产品线延续稳健增长，叠加近期多家机构上调目标价并维持积极评级，带动盘前情绪走强。已披露信息显示，公司上季度产品业务营收33.34亿美元，同比增长12.45%；8月公司还上调全年营收指引至131亿至132亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"福泰制药盘前上涨，财报与机构看多双驱动","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120659580","title":"财报前瞻 | 福泰制药本季营收预计增11.75%，机构观点偏看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1120659580","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120659580?lang=zh_cn&edition=full","pubTime":"2026-10-26 08:03","pubTimestamp":1792972986,"startTime":"0","endTime":"0","summary":"福泰制药将于2026年11月02日美股盘后发布最新季度财报，市场关注主营与管线进展对营收与盈利的边际影响。公司当前主营业务亮点在于成熟产品线形成稳健现金流与高确定性收入基盘，上季度“产品”业务实现33.34亿营收，同比增长12.45%。就发展前景最大的现有业务而言，核心产品组合持续渗透与适应症拓展驱动规模化增长，上季度营收33.34亿、同比增长12.45%，延续增长势头。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | 福泰制药本季营收预计增11.75%，机构观点偏看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198638649","title":"异动解读｜福泰制药盘中上涨3.44%，肾病药物积极数据持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1198638649","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198638649?lang=zh_cn&edition=full","pubTime":"2026-10-15 21:57","pubTimestamp":1792072624,"startTime":"0","endTime":"0","summary":"10月15日，福泰制药盘中上涨3.44%，报514.24美元/股，成交额1.13亿美元。此次异动的消息面，仍与公司此前披露的肾病在研药物Inaxaplin积极临床进展有关。公司此前公布，Inaxaplin在APOL1介导肾病2b期研究中于第13周实现42.7%的蛋白尿降幅，合并2型糖尿病患者降幅为17.3%，且未报告药物相关严重不良事件；同时更大规模的2/3期试验已完成入组。该公司不断创新，推进跨越各种严重疾病的下一代临床和研究项目，包括IgA肾病和1型糖尿病等。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福泰制药盘中上涨，肾病药物数据持续发酵","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172302020","title":"异动解读｜福泰制药盘中上涨3.13%，肾病药物积极数据后股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1172302020","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172302020?lang=zh_cn&edition=full","pubTime":"2026-10-15 03:35","pubTimestamp":1792006512,"startTime":"0","endTime":"0","summary":"10月15日，福泰制药盘中上涨3.13%，报500.5599美元/股，成交额5.74亿美元。此次异动的消息面，仍与公司此前披露的肾病在研药物Inaxaplin积极临床进展有关。公司此前公布，Inaxaplin在APOL1介导肾病2b期研究中，于第13周实现42.7%的蛋白尿降幅，合并2型糖尿病患者降幅为17.3%，且未报告药物相关严重不良事件；同时更大规模的2/3期试验已完成入组。结合近期机构恢复覆盖并给出积极评级，市场对其中长期管线价值预期仍偏正面。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"肾病新药数据亮眼，福泰制药股价上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120836442","title":"异动解读｜福泰制药盘中下跌3.01%，肾病药物利好后市场回吐涨幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1120836442","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120836442?lang=zh_cn&edition=full","pubTime":"2026-10-14 00:07","pubTimestamp":1791907631,"startTime":"0","endTime":"0","summary":"10月14日，福泰制药盘中下跌3.01%，报491.745美元/股，成交额1.42亿美元。近期消息面上，公司此前披露其APOL1介导肾病在研药物inaxaplin在2b期试验中实现42.7%的蛋白尿降幅，合并2型糖尿病患者降幅为17.3%，且未报告药物相关严重不良事件。公司同时表示，13周治疗后取得上述结果，且更大规模的2/3期试验已完成入组。此前多家机构亦上调或恢复覆盖该股，显示基本面预期偏积极；本次股价回落更多体现为利好兑现后的短线波动。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"福泰制药盘中下跌，肾病药物利好兑现后回落","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176882689","title":"异动解读｜福泰制药盘中下跌3.03%，报506.975美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176882689","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176882689?lang=zh_cn&edition=full","pubTime":"2026-10-02 03:05","pubTimestamp":1790881520,"startTime":"0","endTime":"0","summary":"10月1日，福泰制药盘中下跌3.03%，报506.975美元/股，成交额2.18亿美元。福泰制药所在的生物科技行业中，个股表现分化，其中美国联合医疗涨7.48%，Natera涨0.18%，Moderna跌0.4%，再生元制药公司跌2.16%，安进跌2.43%。福泰制药是一家全球性的生物技术公司，致力于为患有严重疾病的个人创造变革性药物，已开发出针对囊性纤维化、镰状细胞病、输血依赖性β地中海贫血和急性疼痛等病症的获批疗法。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198157419","title":"福泰制药宣布Inaxaplin在特定AMKD患者群体中取得积极结果，第13周UACR显著降低42.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1198157419","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198157419?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:06","pubTimestamp":1790082369,"startTime":"0","endTime":"0","summary":"路透社9月22日消息——福泰制药 今日发布重大公告，披露其在APOL1介导肾病额外患者群体中开展的2b期AMPLIFIED研究取得积极成果。详细数据显示，对于伴有中度蛋白尿的AMKD患者，Inaxaplin在治疗第13周时使尿白蛋白肌酐比较基线下降了42.7%。两项研究队列均显示，Inaxaplin总体安全性和耐受性良好，未出现意外安全信号。值得注意的是，这是福泰制药在这两个特定亚群中首次公布Inaxaplin的临床数据，进一步拓展了该药物在AMKD治疗领域的潜在应用范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","GNMX","IE0002270589.USD","LU0079474960.USD","IE00B19Z9P08.USD","TBXU","IBB","LU0432979614.USD","LU1093756168.USD","LU2456880835.USD","LU0289739699.SGD","BK4532","IE00B4R5TH58.HKD","LU0823416689.USD","LU2362540622.SGD","LU0320765992.SGD","LU2362541273.HKD","LU1778281490.HKD","LU2468319806.SGD","SG9999013999.USD","IE0009355771.USD","LU0889565916.HKD","LU2237438978.USD","IE00B19Z3B42.SGD","IBBQ","IE00B19Z9Z06.USD","LU2324357040.USD","PBE","BBH","BK4588","IE00B19Z3581.USD","IE00B2B36J28.USD","LU1674673691.USD","SG9999001176.USD","IE00BJJMRZ35.SGD","LU1035775433.USD","IDNA","LU2089984988.USD","LU1585245621.USD","LU1069344957.HKD","BK4139","BK4585","LU1430594728.SGD","IE0002141913.USD","BK4533","IE00BJT1NW94.SGD","LU0058720904.USD","LU1674673428.USD","SG9999001176.SGD","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","LU2417539215.USD","LU0417517546.SGD","LU2236285917.USD","BIB","LU2462157665.USD","IE00BZ9MQY76.HKD","LU0061475181.USD","VRTX","LU0234570918.USD","LU2362541513.USD","LU0256863811.USD","IE00B894F039.SGD","LU0109394709.USD","BK4567"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196050236","title":"福泰制药：Inaxaplin在两种AMKD患者队列中均展现良好安全性与耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1196050236","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196050236?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:02","pubTimestamp":1790078535,"startTime":"0","endTime":"0","summary":"福泰制药近日披露，其候选药物Inaxaplin在两项针对APOL1介导肾病的临床试验队列中，表现出令人满意的安全性和耐受性特征。业内观察人士指出，Inaxaplin若能在后续研究中持续印证其价值，有望为AMKD这一难治性疾病带来突破性治疗选择。福泰制药此番公告，不仅回应了市场对管线进展的关切，也再次凸显了其在精准医疗赛道上的深耕意图。随着更多数据的积累，Inaxaplin的临床定位将愈发清晰，其对患者生活质量的实际改善程度也将接受更严苛的检验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","LU2089984988.USD","LU0256863811.USD","IE00B894F039.SGD","BK4585","BK4139","LU2462157665.USD","IE00B19Z3581.USD","LU1069344957.HKD","IE00B19Z3B42.SGD","LU1674673428.USD","LU1430594728.SGD","TBXU","LU1035775433.USD","BIB","IE00BJJMRZ35.SGD","LU0889565916.HKD","GNMX","LU2362541513.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","SG9999001176.USD","IE00B2B36J28.USD","LU2236285917.USD","IBBQ","LU1674673691.USD","BK4533","LU1778281490.HKD","IE00B19Z9Z06.USD","LU0823416689.USD","LU2362541273.HKD","IE0002141913.USD","LU1093756168.USD","IE0002270589.USD","LU2456880835.USD","LU0109394709.USD","SG9999001176.SGD","VRTX","LU2468319806.SGD","LU0432979614.USD","BK4588","LU1093756325.SGD","LU2237438978.USD","IE00BZ9MQY76.HKD","IE0009355771.USD","LU1585245621.USD","LU0079474960.USD","SG9999013999.USD","SGXZ57979304.SGD","LU0061475181.USD","IE00B19Z9P08.USD","BK4567","LU2324357040.USD","LU2417539215.USD","LU0289739699.SGD","LU0320765992.SGD","LU2362540622.SGD","PBE","IDNA","BK4532","IBB","LU0417517546.SGD","LU0058720904.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160767959","title":"福泰制药公布Inaxaplin针对APOL1介导肾病（AMKD）其他人群的2B期AMPLIFIED研究积极结果，并完成2/3期AMPLITUDE试验入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1160767959","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160767959?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:01","pubTimestamp":1790078494,"startTime":"0","endTime":"0","summary":"福泰制药今日宣布，其候选药物Inaxaplin在针对APOL1介导肾病其他患者群体的2B期AMPLIFIED研究中，取得了令人鼓舞的积极数据。与此同时，公司还确认，备受瞩目的2/3期AMPLITUDE注册试验已顺利达成全部患者入组目标。目前，该疾病在全球范围内缺乏针对性治疗手段，Inaxaplin有望为患者带来突破性的治疗选择。业内分析人士认为，AMPLIFIED研究的积极结果以及AMPLITUDE试验的顺利入组，进一步巩固了福泰制药在肾脏病精准医疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2089984988.USD","IE00B19Z9Z06.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","LU0058720904.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00B19Z3581.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU1778281490.HKD","IE00B19Z9P08.USD","IE00B19Z3B42.SGD","SG9999001176.USD","LU2362541513.USD","LU1035775433.USD","LU1674673428.USD","LU1093756168.USD","LU2362541273.HKD","LU0889565916.HKD","BBH","IE0002270589.USD","LU2462157665.USD","TBXU","IBBQ","BK4585","LU0823416689.USD","IDNA","LU2324357040.USD","PBE","SG9999013999.USD","BK4533","GNMX","IE0009355771.USD","IE00B894F039.SGD","LU1430594728.SGD","VRTX","LU0079474960.USD","SG9999001176.SGD","LU2362540622.SGD","LU2237438978.USD","LU1585245621.USD","IE00B4R5TH58.HKD","IE00BZ9MQY76.HKD","LU2417539215.USD","LU2456880835.USD","LU0256863811.USD","LU1069344957.HKD","LU2468319806.SGD","LU0432979614.USD","LU1674673691.USD","IBB","IE0002141913.USD","LU0061475181.USD","BK4567","BIB","BK4532","SGXZ57979304.SGD","LU1093756325.SGD","LU2236285917.USD","LU0289739699.SGD","BK4588","LU0234570918.USD","LU0417517546.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191181268","title":"福泰制药：Inaxaplin显著降低UACR达42.7%——针对适度蛋白尿APKD患者展现积极疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1191181268","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191181268?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:01","pubTimestamp":1790078474,"startTime":"0","endTime":"0","summary":"生物制药巨头福泰制药近日披露了一项令人瞩目的临床数据：其候选药物Inaxaplin在治疗伴有适度蛋白尿的常染色体显性多囊肾病患者中，于第13周时使尿白蛋白肌酐比较基线大幅下降42.7%。值得关注的是，这项数据凸显了Inaxaplin在降低蛋白尿方面的显著潜力，而蛋白尿正是衡量肾脏损伤程度及预测疾病进展风险的关键生物标志物。尽管现有数据展现出鼓舞人心的信号，但业界普遍认为，要全面评估Inaxaplin的长期获益与安全性，尚需更大规模、更长周期的临床验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","GNMX","IE0002270589.USD","LU0079474960.USD","IE00B19Z9P08.USD","TBXU","IBB","LU0432979614.USD","LU1093756168.USD","LU2456880835.USD","LU0289739699.SGD","BK4532","IE00B4R5TH58.HKD","LU0823416689.USD","LU2362540622.SGD","LU0320765992.SGD","LU2362541273.HKD","LU1778281490.HKD","LU2468319806.SGD","SG9999013999.USD","IE0009355771.USD","LU0889565916.HKD","LU2237438978.USD","IE00B19Z3B42.SGD","IBBQ","IE00B19Z9Z06.USD","LU2324357040.USD","PBE","BBH","BK4588","IE00B19Z3581.USD","IE00B2B36J28.USD","LU1674673691.USD","SG9999001176.USD","IE00BJJMRZ35.SGD","LU1035775433.USD","IDNA","LU2089984988.USD","LU1585245621.USD","LU1069344957.HKD","BK4139","BK4585","LU1430594728.SGD","IE0002141913.USD","BK4533","IE00BJT1NW94.SGD","LU0058720904.USD","LU1674673428.USD","SG9999001176.SGD","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","LU2417539215.USD","LU0417517546.SGD","LU2236285917.USD","BIB","LU2462157665.USD","IE00BZ9MQY76.HKD","LU0061475181.USD","VRTX","LU0234570918.USD","LU2362541513.USD","LU0256863811.USD","IE00B894F039.SGD","LU0109394709.USD","BK4567"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147475205","title":"福泰制药获Leerink Partners恢复覆盖，给予跑赢大盘评级及594美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1147475205","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147475205?lang=zh_cn&edition=full","pubTime":"2026-09-21 18:04","pubTimestamp":1789985058,"startTime":"0","endTime":"0","summary":"Leerink Partners近日宣布恢复对福泰制药的覆盖研究，并给予该股\"跑赢大盘\"评级。这家华尔街投行同时将目标价设定为594美元，彰显其对福泰制药未来走势的乐观预期。这一动作引发市场广泛关注——毕竟，Leerink Partners在生物医药领域的分析素以严谨著称。其恢复覆盖并给出积极评级，无疑为投资者注入了一针强心剂。值得注意的是，这一评级决定恰逢生物科技板块整体回暖之际。多重因素交织下，福泰制药的股价表现或将迎来新的催化剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2417539215.USD","LU0256863811.USD","LU1778281490.HKD","SG9999013999.USD","LU2456880835.USD","SG9999001176.SGD","BK4567","LU0889565916.HKD","LU0234570918.USD","LU2468319806.SGD","LU2324357040.USD","LU0109394709.USD","LU0320765992.SGD","LU1069344957.HKD","LU1093756325.SGD","IE0002141913.USD","IBBQ","PBE","TBXU","LU1430594728.SGD","IE00B19Z9Z06.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU2462157665.USD","LU0058720904.USD","LU1674673691.USD","LU1093756168.USD","LU0432979614.USD","VRTX","BK4533","BIB","IE0002270589.USD","LU2089984988.USD","LU2236285917.USD","LU2362541513.USD","LU1585245621.USD","LU1035775433.USD","GNMX","LU1674673428.USD","LU0061475181.USD","IE00BJJMRZ35.SGD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","IE0009355771.USD","LU2362541273.HKD","IE00BJT1NW94.SGD","SGXZ57979304.SGD","LU2362540622.SGD","BBH","IE00BZ9MQY76.HKD","BK4532","LU0823416689.USD","LU0289739699.SGD","BK4139","BK4588","BK4585","IBB","IE00B19Z9P08.USD","LU0079474960.USD","LU2237438978.USD","SG9999001176.USD","IDNA","IE00BFTCPJ56.SGD","IE00B894F039.SGD","LU0417517546.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667618474","title":"小摩上调Vertex目标价至560美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667618474","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667618474?lang=zh_cn&edition=full","pubTime":"2026-09-15 10:57","pubTimestamp":1789441023,"startTime":"0","endTime":"0","summary":"摩根大通将Vertex Pharmaceuticals的目标价从515美元上调至560美元，维持“增持”评级。(格隆汇)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260915/32369857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["UUP","VRTX","UDN","VERX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179668253","title":"异动解读｜福泰制药盘中下跌3.1%，报524.945美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179668253","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179668253?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:36","pubTimestamp":1788874615,"startTime":"0","endTime":"0","summary":"9月8日，福泰制药盘中下跌3.1%，报524.945美元/股，成交额3729.83万美元。福泰制药所在的生物科技行业中，个股表现分化，其中安进跌7.47%，艾伯维公司跌2.03%，Moderna跌1.82%，PDS Biotechnology Corporation涨172.36%，Roivant Sciences涨13.6%。大型生物科技股普遍承压，福泰制药跟随板块走弱。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664891714","title":"高盛9月“确信名单”更新：美股纳入福泰制药(VRTX.US) 欧股力推莱茵、Adyen和塔兰克斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2664891714","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664891714?lang=zh_cn&edition=full","pubTime":"2026-09-02 15:20","pubTimestamp":1788333621,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","LU1668664300.SGD","LU0251131958.USD","LU0061475181.USD","LU2468319806.SGD","LU2324357040.USD","TBXU","LU1674673691.USD","LU0289739699.SGD","BBH","LU0942090050.USD","VRTX","LU2237443549.SGD","LU0432979614.USD","SG9999001176.SGD","BIB","IE00B19Z9Z06.USD","PBE","LU2462157665.USD","IE0002141913.USD","LU2456880835.USD","GNMX","LU0868494708.USD","LU2237438978.USD","GSX","LU1144417596.USD","LU1791807156.HKD","LU0096364046.USD","LU2237443978.SGD","LU1868836591.USD","BK4533","IDNA","SG9999001176.USD","BK4127","LU1868837300.USD","LU2471134952.CNY","IEV","BK4588","IE00BJJMRZ35.SGD","IBB","IE00B19Z9P08.USD","VGK","IE00BZ9MQY76.HKD","BK4550","VXUS","BK4585","IE0009355771.USD","LU1868836914.USD","LU2471134523.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664891705","title":"高盛9月“确信名单”更新：美股纳入福泰制药 欧股力推莱茵、Adyen和塔兰克斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2664891705","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664891705?lang=zh_cn&edition=full","pubTime":"2026-09-02 15:20","pubTimestamp":1788333621,"startTime":"0","endTime":"0","summary":"进入秋季，高盛对其美国及欧洲市场的“确信名单”进行了更新，为投资者指明当前最看好的股票方向。本次调整中，美国名单新增一只大型生物科技股，欧洲名单则迎来三家新面孔。美国名单：新增福泰制药，移除盈透证券在美国市场，高盛将 $福泰制药$纳入确信名单，同时移除了 $盈透证券$，调整后名单保留23只股票。高盛还表示，塔兰克斯的国际零售业务是被低估的增长引擎。","market":"us","thumbnail":"https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490866.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2471134796.USD","LU2471134523.USD","MSFU","IDNA","LU2456880835.USD","MSFO","LU0889565916.HKD","CRNX","IE00BFXG1179.USD","IE00BJT1NW94.SGD","LU0106831901.USD","MSFL","LU2417539215.USD","IE00B19Z3581.USD","IE00B2B36J28.USD","LU2471134952.CNY","LU2750360641.GBP","UN","LU1868837136.USD","IBBQ","LU1868837300.USD","XYZG","MSFT","IE0002270589.USD","GSX","BK4567","BK4504","BK4532","MSFY","VGK","DAL","LU2468319806.SGD","LU1868836757.USD","IEV","UNH","UNHG","VRTX","BIB","EL","LU0345770993.USD","BK4533","LU0432979614.USD","PBE","IE0034235188.USD","MSFC","VXUS","MSFW","LU0109394709.USD","UNHW","COP","XYZ","IBKR","UNHU","GNMX","WFC","IE0004091025.USD","IBB","SG9999001176.SGD","IE00BFTCPJ56.SGD","MSFX","LU2265009873.SGD","BK4585","LU1069344957.HKD","LU2362541273.HKD","MSFD","TBXU","LU2236285917.USD","LU2237443549.SGD","LU1585245621.USD","SG9999001176.USD","BBH","XYZY","LU2471134879.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187673248","title":"异动解读｜福泰制药盘中上涨3.04%，多重管线催化剂叠加分析师看好推动股价走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1187673248","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187673248?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:36","pubTimestamp":1787150201,"startTime":"0","endTime":"0","summary":"8月19日，福泰制药盘中上涨3.04%，报543.95美元/股，成交额1.24亿美元。此外，竞争对手囊性纤维化药物研发未达预期，进一步巩固了公司在该领域的主导地位。基本面方面，公司二季度营收33.34亿美元超市场预期，全年收入指引上调至131亿至132亿美元。多家机构维持买入评级，高盛目标价652美元、Jefferies目标价610美元，均显著高于当前股价。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192978278","title":"异动解读｜福泰制药盘中上涨3.09%，多重管线催化剂叠加分析师看好推动股价走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1192978278","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192978278?lang=zh_cn&edition=full","pubTime":"2026-08-19 00:03","pubTimestamp":1787069031,"startTime":"0","endTime":"0","summary":"8月18日，福泰制药盘中上涨3.09%，报531.475美元/股，成交额2.2亿美元。消息面上，RBC Capital近期发布研报指出，福泰制药拥有多个潜在管线催化剂，整体风险收益比偏正面。此外，此前竞争对手药物研发未达预期，进一步强化了公司在囊性纤维化领域的领先地位。公司二季度营收33.34亿美元超预期，全年收入指引上调至131亿至132亿美元，多家机构维持买入评级，目标价普遍高于当前股价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658930620","title":"美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658930620","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658930620?lang=zh_cn&edition=full","pubTime":"2026-08-10 23:39","pubTimestamp":1786376356,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2236285917.USD","LU1674673428.USD","IBBQ","TBXU","IE0002141913.USD","BK4588","LU0256863811.USD","BIB","IBB","LU1674673691.USD","IE00BFTCPJ56.SGD","LU1430594728.SGD","LU0320765992.SGD","LU2462157665.USD","LU1093756168.USD","SG9999001176.SGD","SG9999001176.USD","LU2456880835.USD","GNMX","IE00BJT1NW94.SGD","SG9999013999.USD","IE0002270589.USD","LU0058720904.USD","LU2324357040.USD","VRTX","IE00B19Z9Z06.USD","IE00B19Z3581.USD","LU0289739699.SGD","IE0009355771.USD","PBE","LU2417539215.USD","LU0234570918.USD","LU0417517546.SGD","LU2362540622.SGD","IBBJ","LU2089984988.USD","LU0889565916.HKD","BBH","BK4585","BK4139","LU1035775433.USD","LU1069344957.HKD","LU2362541513.USD","SGXZ57979304.SGD","IE00BZ9MQY76.HKD","LU1778281490.HKD","IE00B19Z9P08.USD","BK4567","LU1585245621.USD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vrtx.com","stockEarnings":[{"period":"1week","weight":0.0667},{"period":"1month","weight":0.069},{"period":"3month","weight":0.1714},{"period":"6month","weight":0.3184},{"period":"1year","weight":0.331},{"period":"ytd","weight":0.2328}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":-0.0091},{"period":"3month","weight":0.0116},{"period":"6month","weight":0.0487},{"period":"1year","weight":0.1116},{"period":"ytd","weight":0.1082}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vertex Pharmaceuticals Incorporated于1989年在马萨诸塞州注册成立，是一家全球性的生物技术公司，致力于科学创新，旨在为患有严重疾病的个人，特别是在专业市场创造变革性药物。该公司已开发出针对囊性纤维化、镰状细胞病、输血依赖性β地中海贫血和急性疼痛等病症的获批疗法。该公司不断创新，推进跨越各种严重疾病的下一代临床和研究项目，包括IgA肾病和1型糖尿病等。","yearOnYearQuotes":[{"month":1,"riseRate":0.657143,"avgChangeRate":0.034393},{"month":2,"riseRate":0.457143,"avgChangeRate":0.001601},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.021959},{"month":4,"riseRate":0.6,"avgChangeRate":0.01636},{"month":5,"riseRate":0.571429,"avgChangeRate":0.076942},{"month":6,"riseRate":0.571429,"avgChangeRate":0.030748},{"month":7,"riseRate":0.457143,"avgChangeRate":-0.005619},{"month":8,"riseRate":0.638889,"avgChangeRate":0.048963},{"month":9,"riseRate":0.472222,"avgChangeRate":0.028245},{"month":10,"riseRate":0.555556,"avgChangeRate":0.002749},{"month":11,"riseRate":0.485714,"avgChangeRate":-0.02026},{"month":12,"riseRate":0.657143,"avgChangeRate":0.071588}],"exchange":"NASDAQ","name":"福泰制药","nameEN":"Vertex Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福泰制药(VRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福泰制药(VRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福泰制药,VRTX,福泰制药股票,福泰制药股票老虎,福泰制药股票老虎国际,福泰制药行情,福泰制药股票行情,福泰制药股价,福泰制药股市,福泰制药股票价格,福泰制药股票交易,福泰制药股票购买,福泰制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福泰制药(VRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福泰制药(VRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}